医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Muchen Launches Oclean Xpro, the Smart Electric Toothbrush

2021年03月08日 PM10:51
このエントリーをはてなブックマークに追加


 

SHENZHEN, China

At the dawn of this International Women’s Day, Muchen launches the smart electric toothbrush, Oclean Xpro. It has a powerful eight-blind spot monitoring function, and the results are directly displayed on the large touch screen of the toothbrush body. It can also match professional toothbrushing programs for oral conditions and eating habits, while also supporting custom plans to allow women during pregnancy to take care of their own oral cavity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005515/en/

Muchen launches Oclean Xpro special electric toothbrush for oral health (Photo: Business Wire)

Muchen launches Oclean Xpro special electric toothbrush for oral health (Photo: Business Wire)

On women’s day, many countries will hold commemorations and celebrations to call attention to women’s social status. While paying attention to women’s rights and status, people must not forget women’s health. Caring for women’s health starts with oral health.

Dentists recommend that pregnant women pay more attention to tooth cleaning, and electric toothbrushes are the recommended product, which can effectively and conveniently care for the oral cavity. For people who want an easy-to-operate electric toothbrush, this world’s quietest electric toothbrush Oclean Air2 will be the best choice. It has strong cleaning power and is equipped with active noise reduction and mute technology.

This Women’s Day is a great occasion to make women’s oral health as important as women’s social status.

For details, please click: https://bit.ly/3qcVJta

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005515/en/

CONTACT

Company Name:Shenzhen Muchen Technology Co., Ltd., China

Contact Person:Taylor Qu

Email:bbeng8529@gmail.com

Website:https://muchenworld.com

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表